Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 40673-25-4 | MDL No. : | MFCD03093022 |
Formula : | C5H4ClNO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | OZUXGFRLSKQVMI-UHFFFAOYSA-N |
M.W : | 129.54 | Pubchem ID : | 2757611 |
Synonyms : |
|
Num. heavy atoms : | 8 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 31.27 |
TPSA : | 33.12 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.05 cm/s |
Log Po/w (iLOGP) : | 1.47 |
Log Po/w (XLOGP3) : | 1.46 |
Log Po/w (WLOGP) : | 1.44 |
Log Po/w (MLOGP) : | 0.81 |
Log Po/w (SILICOS-IT) : | 1.61 |
Consensus Log Po/w : | 1.36 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.12 |
Solubility : | 0.987 mg/ml ; 0.00762 mol/l |
Class : | Soluble |
Log S (Ali) : | -1.76 |
Solubility : | 2.24 mg/ml ; 0.0173 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -2.03 |
Solubility : | 1.21 mg/ml ; 0.00938 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.35 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
58% | at 50℃; for 16 h; sealed tube | 4-Chloro-2-hydroxy-pyridine (247 mg, 1.91 mmol), Ag2CO3 (1.58 g, 5.74 mmol) and MeI(0.13 ml, 2.11 mmol) were heated in a sealed tube at 50 0C for 16 hours and then filtered through celite and concentrated at reduced pressure. The residue was purified by FCC (Pentane/Diethyl ether with gradient, 99:1 to 95:5) to provide the title compound as colourless oil (160 mg, 58percent).LCMS data: Calculated MH+ (144); Found 100percent (MH+) m/z 144, Rt = 1.71 min.NMR data: 1H NMR (500 MHz, CDCl3) δ ppm 8.07 (1 H, d, J=5.5 Hz), 6.89 (1 H, dd, J=5.5,1.5 Hz), 6.77 (1 H, d, J=1.7 Hz), 3.94 (3 H, s). |
[ 1807199-46-7 ]
4-Chloro-2-(difluoromethoxy)pyridine
Similarity: 0.78
[ 245124-17-8 ]
(4-Chloropyridin-3-yl)methanol hydrochloride
Similarity: 0.75
[ 189449-41-0 ]
(4-Chloropyridin-3-yl)methanol
Similarity: 0.75
[ 245124-17-8 ]
(4-Chloropyridin-3-yl)methanol hydrochloride
Similarity: 0.75
[ 1807199-46-7 ]
4-Chloro-2-(difluoromethoxy)pyridine
Similarity: 0.78
[ 245124-17-8 ]
(4-Chloropyridin-3-yl)methanol hydrochloride
Similarity: 0.75